Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan’s Fulphila: First Neulasta Biosimilar’s Road To US Market Slowed Only By Product Quality, GMP Deficiencies

Nov 08 2018

• By Sue Sutter

Related Content

Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry

Jun 15 2018

US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals

May 29 2018

Keeping Track: FDA Starts November With A Bang

Nov 02 2018

Fulphila Clinical Development Timeline

Nov 08 2018

US FDA Ends Nearly 2-Year Drought In Biosimilar Action Package Postings

Nov 08 2018

Fulphila Reviewers

Nov 08 2018

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Jun 12 2017

Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy

Jun 13 2017

Will FDA GMP Observations Stall Biocon’s Run?

Aug 07 2017

How Biocon Site Prevented FDA 'OAI' Finding From Derailing Biosimilars

Dec 12 2017

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Jul 12 2018

Related Companies

Viatris Inc.

Amgen, Inc.

Novartis AG

Biocon, Ltd.

Apotex Inc.

Coherus Oncology, Inc.

Becton, Dickinson and Company

Additional Topics

United States Biosimilars Biologics Regulation Manufacturing Drug Review Profile Cancer BioPharmaceutical

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window